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Abstract: Acute myeloid leukemia (AML) is a heterogeneous group of fast
growing cancers of myeloid progenitor cells, for which effective
treatments are still lacking. Identification of signaling inhibitors that
block their proliferation could reveal the proliferative mechanism of a
given leukemia cell, and provide small molecule drugs for targeted
therapy for AML. In this study, kinase inhibitors that block the majority
of cancer signaling pathways are evaluated for their inhibition of two
AML cell lines of the M5 subtypes, CTV-1 and THP-1. While THP-1 cells do
not respond to any of these inhibitors, CTV-1 cells are potently
inhibited by dasatinib, bosutinib, crizotinib, A-770041, and WH-4-23, all
potent inhibitors for Lck, a Src family kinase. CTV-1 cells contain a
kinase activity that phosphorylates an Lck-specific peptide substrate in
an Lck inhibitor-sensitive manner. Furthermore, the Lck gene is overexpressed in CTV-1, and it contains four mutations, two of which are
located in regions critical for Lck negative regulation, and are
confirmed to activate Lck. Collectively, these results provide strong
evidence that mutated and overexpressed Lck is driving CTV-1
proliferation. While Lck activation and overexpression is rare in AML,
this study provides a potential therapeutic strategy for treating
patients with a similar oncogenic mechanism.

*Highlights

Highlights
The proliferation of CTV-1 AML cells are potently inhibited by Lck kinase inhibitors
CTV-1 lysate contains Lck kinase activity
Lck gene in CTV-1 is over-expressed, and contains four mutations
Two of the mutations disrupt negative regulation to activate Lck
The first natural cell line driven by a constitutively activated Src family kinase
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Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of fast growing cancers of myeloid
progenitor cells, for which effective treatments are still lacking. Identification of signaling
inhibitors that block their proliferation could reveal the proliferative mechanism of a given
leukemia cell, and provide small molecule drugs for targeted therapy for AML. In this study,
kinase inhibitors that block the majority of cancer signaling pathways are evaluated for their
inhibition of two AML cell lines of the M5 subtypes, CTV-1 and THP-1. While THP-1 cells do
not respond to any of these inhibitors, CTV-1 cells are potently inhibited by dasatinib, bosutinib,
crizotinib, A-770041, and WH-4-23, all potent inhibitors for Lck, a Src family kinase. CTV-1
cells contain a kinase activity that phosphorylates an Lck-specific peptide substrate in an Lck
inhibitor-sensitive manner. Furthermore, the Lck gene is over-expressed in CTV-1, and it
contains four mutations, two of which are located in regions critical for Lck negative regulation,
and are confirmed to activate Lck. Collectively, these results provide strong evidence that
mutated and overexpressed Lck is driving CTV-1 proliferation. While Lck activation and
overexpression is rare in AML, this study provides a potential therapeutic strategy for treating
patients with a similar oncogenic mechanism.
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1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of fast growing cancers of
myeloid progenitor cells. Based on the cell type and the stage at which the cellular development
is disrupted, AML is divided into eight subtypes, M0 through M7 [1]. Multiple genetic mutations
are known to play key roles in the development of AML [2, 3]. These mutations can inactivate
transcription factors, such as AML1/ETO [4], CBF/SMMHC [5, 6], PML-RARa [7], or MLL
fusion proteins [8, 9], to disrupt differentiation [10, 11], confer the cell sustained proliferation
and an escape from apoptosis [11], or affect epigenetic modifications [3, 11, 12].
Despite a general understanding of AML genetic landscape, AML is notoriously
heterogeneous, and the driver mutations in most AML cell lines have not been identified. With
the exception of FLT3 inhibitors [13] in clinical development, targeted and specific therapy is
still not available for most AML patients. Treatment of AML patients still mostly relies on the
anthracycline-cytarabine regimen designed more than four decades ago [14].
An M5 AML patient has more than 20% blasts in the bone marrow, and more than 80%
of the blasts are of monocytic lineage [1]. Some chromosomal abnormalities affecting MLL, a
global transcription regulator, have been well documented in M5 [15-16]. What signaling
mechanisms sustain M5 cell proliferation is not clear. Treatment of M5-AML relies on
traditional chemotherapy and bone marrow transplantation.
Lck is a 56 kD protein tyrosine kinase in the Src family, and it is most commonly
expressed in T lymphocytes [17]. It associates with the cytoplasmic tails of T cell co-receptors,
CD4 and CD8. Engagement of T-cell surface receptors with antigen presented by MHC activates
Lck, which then phosphorylates substrates, including CD3, ζ chain of TCR and ZAP-70, leading
to T cell activation [18]. To play this normal physiological role, Lck is under tight regulation by
3

autophosphorylation (Tyr394, activation), and Csk phosphorylation (Tyr505, inactivation) [19].
Like other members in the Src family, constitutively activated Lck caused by mutation is
oncogenic [20-21], even though there is no report of Lck mutants being responsible for naturally
occurring cancers or cancer cell lines.
In this study, we use small molecule inhibitors against various oncogenic protein tyrosine
kinases to probe for the key drivers of proliferation in two M5 AML cells, CTV-1 [23-24] and
THP-1 [25-26]. The inhibition profiling suggests that Lck protein tyrosine kinase is the key
oncogenic driver of CTV-1 cell proliferation, which is confirmed by molecular and mutagenic
analyses. In contrast, the THP-1 cells do not rely on any signaling pathways tested to sustain its
proliferation. These results shed light on the proliferative mechanism of an M5 cell line of AML.
AML cells rarely express Lck, and there is evidence that the overexpression and activation of
Lck in CTV-1 cells may be due to lineage switching from T-cell acute lymphoblastic leukemia to
AML. This study provides a foundation for developing therapeutic strategies against this subtype
of AML.

2. Materials and Methods
2.1. Cell culture and treatment
The AML cell lines CTV-1 (purchased from DSMZ, Braunschweig, Germany) and THP1 (purchased from ATCC, Manassas, VA, USA) were grown in RPMI1640 containing 10% FBS
and 1% Penicillin – streptomycin at 37℃ in humid atmosphere containing 5% CO2. Kinase
inhibitors were purchased from Selleckchem (Munich, Germany), LC Laboratories (Woburn,
MA, USA) or AdooQ Bioscience (Irvine, CA, USA). Biolog Redox Dye Mix MA or MB
(Biolog Inc. Cabot Blvd. Hayward CA, USA) was used to stain the cells for viability assays.
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Cells were plated onto 96-well plates at 5x104 cells/well, and were incubated with 16
different concentrations (0.0006 μM-20 μM) of each kinase inhibitor for 72h. The viable cells
were determined by staining the cells with Biolog Redox Dye Mix MA or MB, and measuring
the absorbance of the water soluble formazan product from the dye reduction using a VersaMax
Tunable Microplate Reader at 590 and 750 nm. The absorbance values of A590-A750 were
taken as indicator of cell viability. Each experiment was done in triplicate, and repeated at least
three times independently. The average and standard deviation for each treatment were
calculated in Microsoft Excel. Outlier readings judged as inconsistent with other readings in the
same treatment were removed.

2.2. The expression level of Lck protein in the leukemia cell lines
Approximately 1.25×108 CTV-1, THP-1and GDM-1 cells were lysed in 200 μl lysis
buffer (Tris-HCl 50mM, NaCl 150mM, EDTA 1mM, Triton-X-100 0.05%). The lysates were
mixed with an equal volume of 2X SDS-PAGE loading buffer, and heated for 10 minutes at
95oC. After quick spin down, the denatured lysates (10 μl) were loaded into each well on the
ready-gel (Bio-Rad, CA, 94547, USA) for electrophoresis. The fractionated proteins were
transferred onto a nitrocellulose membrane using semi-dry transfer cell (Bio-Rad, CA 94547,
USA), and the membrane was blocked for 1 hour using 5% milk. The membrane was rinsed 3
times using Tris-buffered saline with Tween 20 (TBST), and then incubated with an Lck rabbit
monoclonal antibody (Cell Signaling, Danvers, MA) at 4℃ overnight with gentle shaking.
After washing three times with TBST for 3 min each, the membrane was incubated with a
secondary antibody (anti-rabbit IgG, Sigma, Billerica, MA 01821) for 1 hour. After rinsing 3
times with TBST for 3 min each, the secondary antibody attached to the membrane was detected
5

by SuperSignal west pico (SuperSignal™ Pico Chemiluminescent Substrate (Thermo
Scientific™). The images were generated using conventional X-ray films. β-Actin detected by a
monoclonal antibody (Cell Signaling, Danvers, MA) was used as loading control.

2.3. Lck activity in cell lysates
CTV-1 cells were harvested and washed twice in phosphate buffered saline (PBS).
Approximately 1.25×108 CTV-1 cells were lysed in 200 μl lysis buffer (Tris-HCl 50 mM, NaCl
150 mM, EDTA 1 mM, 0.005% Triton-X-100). The cell lysate (10 l) and 10 l kinase assay
buffer was added to 20 μl Lck peptide substrate, GST-AEEEIYGVLFAKKKK (1 mg/ml). An
aliquot of 10 μl of ATP cocktail (final concentration: ATP 0.2 mM, 12 mM MgCl2) was added to
initiate the reaction. When the effect of inhibitors was determined, the kinase inhibitor, dasatinib
or A-770041, was included in the kinase assay buffer (final concentration = 1 M). After 30 min
reaction, the reactions were mixed with equal volume of SDS-PAGE loading buffer and prepared
for SDS-PAGE and Western Blotting. Tyrosine phosphorylation on Lck peptide substrate and
cellular proteins was detected using a mouse monoclonal antibody against phosphotyrosine, and
a secondary anti-mouse IgG antibody (Sigma, 3050 Spruce St. St. Louis, MO). Western blotting
was performed as described above.

2.4. Kinase activity assay of wt Lck and Lck mutants in vitro
The wt human Lck coding gene was cloned into pGEX-4T-1, and the wt Lck enzyme was
expressed as a GST fusion protein. Lck mutants, each containing a mutation found in CTV-1
cells were generated via Quikchange using wt-Lck in pGEX-4T-1 plasmid as template. The
primers used for generating the Lck mutants are listed in Table 1.
6

All constructs were confirmed by DNA sequencing. The wt and each of the Lck mutants
were expressed in DH5 bacterial cells, and purified by glutathione affinity chromatography as
previously described [27]. Briefly, the DH5 bacterial cells harboring the pGEX-Lck or mutant
were inoculated in 10 ml LB medium for overnight culture at 37oC. The overnight culture was
mixed with 500 ml fresh LM medium, and cultured at room temperature until the OD600
reached 1. The Lck expression was then induced by 0.5 mM isopropyl β-D-1thiogalactopyranoside (IPTG) for 4 hours. The cells were harvested by centrifugation. The four
Lck mutants generated are P232_W233insQKP, A353V, P447L, and A500T.
GST-Lck mutants were purified on ice as previously described [2]. Protein concentrations were
determined by Bradford protein assay using bovine serum albumin as a standard.

2.5. The activity of wild type and mutants of Lck
For analysis of Lck and mutant activities, we measured the phosphorylation of the Lck
peptide substrate using Western blot method. A standard assay reaction of 50 μL contained the
purified kinase (10 l), the peptide substrate (20 μl, final concentration 1 mg/ml), ATP cock tail
(10 μl), and the kinase assay buffer (75 mM 4-(2-hydroxyethyl)piperazine-1-propanesulfonic
acid [EPPS], pH8.0, 12 mM MgCl2, 5% glycerol, and 0.005% Triton X-100) (10 μl). After the
reaction at room temperature for 30 min, 40 μl reactions were mixed with equal volumes of 2X
loading SDS-PAGE loading buffer. The phosphorylation of the peptide substrate was determined
by Western blotting using a monoclonal antibody against phosphotyrosine as described earlier.
The band density was measured using the ImageJ software
(https://imagej.nih.gov/ij/download.html).
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3. Results
3.1. Protein tyrosine kinase inhibitors are used to probe the oncogenic signaling of CTV-1
and THP-1 cells
To identify the drivers of proliferation in the two M5 AML cell lines, CTV-1 and THP-1,
we determined their sensitivity to a panel of PTK inhibitors. CTV-1 is a human monocytic
leukemia cell line established from a 40 yr-old male patient with relapsed acute monoblastic
leukemia [23-24]. THP-1 is a monocytic cell line established from a 1-yr old male patient of
acute monocytic leukemia [25]. CTV-1 has been barely studied, while THP-1 has been
extensively characterized as a model cell line for studying differentiation of monocytes and
macrophages [26]. The proliferative driver for either cell line has not been identified.
In order to determine what signaling pathways are important for the proliferation of these
cells, 10 PTK inhibitors that collectively target most of the oncogenic signaling pathways are
selected (Table 2). Eight of the inhibitors have been tested for the binding affinities toward most
of the protein kinases in the human kinome (http://lincs.hms.harvard.edu/kinomescan/), and they
bind to the target PTKs with in vitro Kd value below 20 nM. Two of the inhibitors, BMS-754807
and BGJ398, have not been tested against the kinome, but their specificities have been evaluated
toward a large number of PTKs in the original studies. BMS-754807 specifically inhibits
receptor PTKs in the insulin receptor family and Met [28-29], and BGJ398 inhibits receptor
PTKs of the FGFR family [30]. Considering that insulin receptor, insulin-like growth factor
receptor and FGFR kinases are potentially important oncogenic enzymes, these two inhibitors
are also included in this study. There are 33 cancer census PTK genes [31] distributed in PTK
families, such as Src, Abl, PDGFR, EGFR, FGFR, etc. The only cancer census PTK that is not
inhibited by at least one of these inhibitors is EphA7. If any of these target PTKs is important for
8

the proliferation of CTV-1 or THP-1, the proliferation of the cell line should be inhibited by the
respective inhibitors.

3.2. Drug sensitivity analysis suggests a Src family kinase, Lck, is essential for the
proliferation of CTV-1 cells
The dose responses of both cell lines to each inhibitor at 16 concentrations from 0.6 nM
to 20 M were determined (Fig. 1). Seven inhibitors did not achieve 50% inhibition of CTV-1
proliferation even at 20 M (neratinib, sunitinib and BMS754807), or displayed IC50 values
between 1 and 5 M (BGJ398, NVP-TAE684, imatinib and linifanib) (Fig. 1). These results
suggest that their intended targets, the kinases in the EGFR, PDGFR, and insulin receptor
families, among others, do not play significant roles in driving CTV-1 proliferation. Based on
this result, the following kinase families are eliminated: EGFR, FGFR, PDGFR, Insulin receptor,
IGF-1R, and Abl. Four inhibitors, BGJ398, NVP-TAE684, imatinib and linifanib displayed IC50
values between 1 and 5 M. Because these inhibitors bind to their intended PTK targets with Kd
values below 20 nM, the IC50 values above 1 M are likely due to interactions with non-specific
targets. For example, imatinib binds to kinases in the Abl family and some members in the
PDGFR family with Kd values below 15 nM. If these Abl and PDGFR kinases are important for
CTV-1 proliferation, imatinib would likely have inhibited CTV-1 proliferation much more
potently. It has been reported that imatinib inhibits the proliferation of numerous cell lines
dependent on Philadelphia Chromosome with IC50 below 600 nM [32].
Three inhibitors displayed IC50 values below 1 M: dasatinib (13 nM), bosutinib (50 nM)
and crizotinib (251 nM) (Fig. 1A). These IC50 values are likely the result of the inhibitors
blocking certain high affinity target(s) that is(are) essential for the proliferation of the CTV-1
9

cells. Dasatinib and bosutinib most potently inhibit PTKs of the Src and Abl families, two of the
most common oncoprotein families. Both inhibitors also display differing levels of inhibition
toward other PTKs, such as members in the Abl, BRK, and PDGFR families. Kinases of the
PDGFR family are eliminated as potential drivers for CTV-1 proliferation because CTV-1
proliferation was not inhibited by sunitinib and linifanib. Abl1 and Abl2 also do not play an
important role in the proliferation of CTV-1 because CTV-1 proliferation is not potently
inhibited by imatinib (Fig. 1B). The elimination of these targets leaves the Src family kinases as
the most plausible candidates for sustaining the proliferation of CTV-1. Crizotinib also inhibited
CTV-1 proliferation with an IC50 of 251 nM. Crizotinib is best known as a Met/Alk kinase
inhibitor (Table 2), with respective Kd’s of 2.1 nM and 7.8 nM, but it also binds to Src family
kinase, Lck, with a Kd of 30 nM (http://lincs.hms.harvard.edu/kinomescan/). Interestingly,
crizotinib has a much higher Kd for Src at 560 nM. Alk is also a target of NVP-TAE684, and Met
is also a target of BMS-754807, and both of these inhibitors did not potently inhibit CTV-1
proliferation. These considerations eliminate Met and Alk, and leave Lck as the most logical
target for crizotinib. Thus, all three potent inhibitors of CTV-1 proliferation have one thing in
common: they all inhibit Lck, suggesting that Lck is the most likely driver for CTV-1
proliferation.
Although both THP-1 and CTV-1 are M5 AML cells, their responses to the PTK
inhibitors are remarkably different. THP-1 is not inhibited by any of the inhibitors (Fig. 1),
indicating that THP-1 cells do not rely on any of the probed pathways for proliferation. More
specifically, while Lck appears to be the driver of CTV-1 proliferation, THP-1 cells do not rely
on Lck for proliferation.

3.3. CTV-1 is inhibited by Lck-specific inhibitors
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The Src family contains eight PTKs with similar structures and similar responses to most
kinase inhibitors [33-34]. The inhibition of CTV-1 proliferation by dasatinib and bosutinib does
not provide any clue as to which SFK kinase might be driving CTV-1 proliferation. The
inhibition by crizotinib, however, favors Lck as the likely proliferative driver because Lck is the
only Src family kinase that binds crizotinib relatively tightly (Kd = 30 nM). To further confirm
that Lck is responsible for CTV-1 proliferation, we determined if CTV-1 proliferation is
sensitive to Lck-specific inhibitors. A-770041 is an inhibitor able to differentiate Lck (IC50 = 147
nM) from other Src family kinases (Src IC50 = 9.1 M, Fyn IC50 = 44.1 M, Fgr IC50 = 14.1 M,
Hck IC50 = 1.22 M, Lyn IC50 = 1.18 M) [35-36]. While these data suggest that A-770041 is a
specific inhibitor against Lck, it has not been tested against the complete kinome, it is possible
that it could inhibit other PTKs.
CTV-1 is indeed very sensitive to A-770041, with an IC50 of 224 nM, with near complete
inhibition of proliferation reached at 400 nM (Fig. 2A). This potent IC50 provides the strongest
evidence that Lck, and not Src, is driving CTV-1 proliferation. The potent sensitivity of CTV-1
cells to A-770041 forms a direct contrast to another AML cell line, GDM-1. As shown in Fig. 2B,
GDM-1 cells are extremely sensitive to dasatinib (IC50=10 nM), but much less sensitive to A770041 with an IC50 of approximately 6 M, demonstrating the differing specificity of A-770041
and dasatinib. WH-4-023 is another potent inhibitor toward Lck [37], with a reported IC50 of 0.6
nM. Based on the initial characterization of this inhibitor against a small panel of PTKs, it
inhibits Lck and Src with similar IC50, at least 100 times better than other non-Src family kinases
[37]. CTV-1 proliferation is also inhibited by WH-4-023 with an IC50 of 700 nM. The unique
sensitivity of CTV-1 proliferation toward A-770041 provides further evidence for Lck as the
driver of CTV-1 proliferation.
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3.4. Lck in CTV-1 contains several mutations and is over expressed in CTV-1 cells
We then examined the genetic information of CTV-1 available from the Catalogue of
Somatic Mutations in Cancer (https://cancer.sanger.ac.uk/cell_lines/sample/overview?id=753548)
[38]. CTV-1 contains 3700 mutated genes and 151 mutated cancer census genes. Based on the
genomic information alone, it is impossible to attribute the growth properties to any of these
mutations. In comparison, THP-1 contains only 345 mutated genes and 19 mutated cancer census
genes. Among the 8 Src family kinases, Lck in CTV-1 contains 4 mutations
(P232_W233insQKP, P447L, A353V, and A500T), and its mRNA is also over expressed, with a
Z-score of 3.88. This expression level makes CTV-1 the highest expresser of Lck among all the
cells in which Lck expression data is available in the database. In contrast, Lck is not overexpressed in THP-1, nor does it contain any mutations. Interestingly, Src also contains one
mutation in CTV-1, Q222H. This genomic information suggests that Lck may be activated by
mutation in addition to its over-expression, consistent with the drug sensitivity data that suggest
that Lck drives CTV-1 proliferation.
To confirm that CTV-1 over-expresses Lck at the protein level, as suggested by the
elevated mRNA level, we determined its protein expression level in CTV-1 and THP-1 by
Western blotting. In this experiment, we also included another AML cell line, GDM-1 [39]. As
shown in Fig. 3B, Lck is readily detectable in CTV-1, but undetectable in THP-1, nor in GDM-1.
The lack of Lck expression in THP-1 and GDM-1 is consistent with the current understanding of
Lck tissue distribution. Lck is known to be specifically expressed in T-cells [17], and is not
known to be expressed in other cell types. In this regard, the lack of Lck expression in THP-1
and GDM-1 is consistent with their myeloid origin, while the Lck over-expression in CTV-1 is
12

abnormal and likely related to its oncogenic signaling. It is established that Lck overexpression is
able to cause tumorigenesis [20-22].

3.5. CTV-1 contains a kinase activity that phosphorylates an Lck peptide substrate in an Lck
inhibitor sensitive manner
We next compared the kinase activity in CTV-1 and THP-1 using an Lck specific peptide
substrate, EEEIYGVLF. This peptide substrate was previously identified using a random library
screening [40]. The peptide substrate sequence is fused to the C-terminus of glutathione S
transferase and purified by glutathione affinity chromatography, and then used as an Lck
substrate. CTV-1 lysate was incubated with the peptide substrate in the presence of ATP-Mg in a
kinase assay buffer, and the phosphorylation of the peptide was determined by Western blotting
using a monoclonal antibody against phosphotyrosine. As shown in Fig. 3A, incubation of CTV1 cell lysate with ATP resulted in Tyr-phosphorylation of extensive number of proteins. When
the peptide substrate was included, the peptide was phosphorylated, indicating that CTV-1 lysate
contains a protein tyrosine kinase activity that is able to phosphorylate this peptide substrate.
Furthermore, both dasatinib and A-770041 at 1 M completely blocked the phosphorylation of
this peptide substrate. The inhibitors did not significantly affect the presence of other
phosphorylated proteins, indicating that phosphorylation of majority of the cellular proteins is
not catalyzed by a kinase sensitive to these inhibitors. The inhibitory specificity of A-770041 for
Lck suggests that the peptide substrate is indeed phosphorylated by Lck. The THP-1 lysate was
also used in a similar experiment as a control. To our surprise, THP-1 also contains a kinase
activity that is able to phosphorylate the peptide substrate (Fig. 3B). However, this kinase
activity is not sensitive to dasatinib or A-770041, indicating that a non-Lck kinase activity in
13

THP-1 is also able to phosphorylate this substrate. The presence of a non-Lck kinase activity that
was able to phosphorylate the peptide substrate was not expected, but not too surprising. Protein
tyrosine kinases are notoriously lacking in specificity toward peptide substrates, and many PTKs
are able to phosphorylate similar peptide substrates. These above results combined further
demonstrate that CTV-1 proliferation is indeed driven by activated Lck activity in the cell.

3.6. Mutations in CTV-1 Lck activate its kinase activity
As noted earlier, Lck in CTV-1 contains four mutations, P232_W233insQKP, P447L,
A353V, and A500T. Because there are two copies of the Lck gene in CTV-1, it is not clear if all
four mutations are present in one copy or distributed in both alleles. Examination of the four
mutations in the context of Lck regulation suggests a clear mechanism for at least two of these
mutations to activate Lck. Src family kinases are negatively regulated by domain-domain
interactions between the catalytic domain and the regulatory SH3 and SH2 domains [33-34].
This negative regulation is triggered by the binding of phosphorylated C-terminal tail Tyr residue
(Tyr505 in Lck) to the SH2 domain, but it also requires the interactions of the SH2-catalytic
domain linker with the SH3 domain and the catalytic domain [41-43]. One of the Lck mutations
in CTV-1 is an insertion of three residues, 232QKP, in the SH2-catalytic domain linker. It is
established that mutations in this region can abolish the negative regulation of Src, Lck and other
Src family kinases [41, 44-45]. Another mutation is A500T, a residue located in the region that
interacts with Csk which phosphorylates the c-terminal tail Tyr of Src family kinases [46-48].
These mutations would be expected to impair Lck inactivation and thus to activate Lck. Because
full length Lck structure is not available and Src and Lck are similar in general structure and
regulation, the regulated structure of Src [43] and the corresponding positions of the four Lck
14

mutations are shown in Fig. 4A to illustrate the positions of these mutations. We determined the
effects of each of the four mutations on the kinase activity of Lck by expressing, purifying and
characterizing the wildtype and each of these mutant Lck variants. Purified GST-Lck variants
were incubated with or without the peptide substrate under phosphorylating conditions, and the
levels of peptide and Lck phosphorylation on Tyr was detected with a phosphor-Tyr antibody.
Indeed, both mutations (P232_W233insQKP and A500T) activated Lck activity toward the
peptide substrate, while all Lck mutants displayed similar levels of Lck autophosphorylation (Fig.
4B). Quantification of the band intensity of the phosphorylated Lck peptide substrate revealed
that P232_W233insQKP and A500T increased Lck activity by 1.9-fold and 3.7 fold, respectively.
These mutations and Lck over-expression in CTV-1 cells provide the molecular basis of Lck
activation, which drives CTV-1 proliferation. It is well established that activated Lck and other
Src family kinases are potent oncoproteins capable of transforming cells [20-22].

4. Discussion
The molecular mechanisms driving the proliferation of M5 subtypes of AML are mostly
unknown. In this paper, we provide strong evidence that the proliferation of CTV-1 cell is driven
by activated and over-expressed Lck. This conclusion is supported by three lines of evidence.
First, CTV-1 proliferation is potently inhibited by five inhibitors that block Lck kinase activity,
but not by other inhibitors that collectively inhibit majority of the protein tyrosine kinome,
including most other cancer census PTKs. One of the potent inhibitors is A-770041, which
inhibits Lck selectively even among Src family kinases. The fact that CTV-1 proliferation is only
inhibited by Lck inhibitors indicates that Lck is specifically essential for CTV-1 proliferation.
Second, Lck is over-expressed at the mRNA and the protein levels, and contains four mutations
15

in CTV-1 cells. Two of the mutations are located in regions critical for Lck negative regulation
and directly activate Lck kinase activity. Finally, CTV-1 lysate contains a kinase activity that
phosphorylates an Lck peptide substrate and this activity is blocked by Lck-specific inhibitors.
This work not only established a likely proliferative mechanism for CTV-1, it also provides a
mechanistic basis for treating leukemia patients with a similar mechanism. Even though Src
family kinases are well established oncogenes, CTV-1 is the first naturally occurring cell line in
which a Src family kinase, activated by overexpression and mutation, is the main driver of
proliferation.
While the results from this study strongly support Lck as the proliferative driver for
CTV-1, inhibitor-based studies are invariably limited by the issue of specificity and off-target
effects. Similarities among Src family kinases in their structure, biochemical function, and
inhibitor response make it especially difficult to distinguish the contribution of one Src family
kinase from that of another. For example, A-770041 has been shown to be a specific inhibitor for
Lck (IC50=147 nM) over Src (IC50 = 9.1 M) [35-36], but another study indicates that A-770041
is able to inhibit Src activation at sub-M concentrations (49). Thus it is possible that Src may
also contribute to the proliferation of CTV-1 cells. Furthermore, there is a possibility that some
other kinases could also be blocked fully or partially by the inhibitors, which would contribute to
the CTV-1 response to the inhibitors. Abl is another PTK that is also sensitive to several of the
inhibitors that block CTV-1 proliferation, such as dasatinib and bosutinib. The insensitive
response to imatinib by CTV-1 (IC50=2.5 M) suggests that Abl is not a major contributor to
CTV-1 proliferation, because BCR-Abl-dependent cell proliferation is inhibited by imatinib with
IC50’s between 80 and 600 nM (32). However, other factors may render Abl-dependent cells less
sensitive to imatinib, leaving Abl as a possible, albeit unlikely, candidate in CTV-1. Considering
16

these possibilities, future genetic experiments targeting Lck and other Src family kinases are
needed to ascertain that Lck is indeed the driver of CTV-1 proliferation.

4.1. Kinome-wide drug sensitivity profiling can identify the signaling pathway that is
essential for a cell’s proliferation
Because of the complexity of the cellular signaling network, the diversity of potential
mechanisms driving the proliferation of a given cancer cell, and the large number of mutations a
cancer cell may contain, determining the driver mutations sustaining a cell’s proliferation is often
a difficult task. That point is further underlined by the genomic information of CTV-1. With
several thousand genes mutated in CTV-1, it is virtually impossible to predict what mutation or
combination of mutations may be driving the proliferative phenotype. Predicting proliferative
signaling mechanisms by proteomic information is also complicated because a large number of
proteins often display altered expression profiles in cancer cells versus a normal cells. The
current study of CTV-1 and THP-1 demonstrates that drug sensitivity profiling to a large number
of signaling blockers can provide a direct and functional identification of the signaling pathway
that drives the proliferation of a given cancer cell. The shortcoming of this approach is also made
clear in this study by THP-1, which does not seem to be inhibited by any of the tested signaling
drugs. It is possible that the proliferation of THP-1 is driven by multiple signaling pathways that
are activated, thus no particular pathway is essential for its proliferation. This study suggests that
signaling drug sensitivity profiling is a useful tool in combination with genomic and proteomic
analyses in elucidating the oncogenic mechanism of a given cancer cell.
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4.2. CTV-1 is a poorly understood AML cell line with some T-cell lymphoblastic leukemia
characteristics
CTV-1 cell line was established as a human monocytoid leukemia cell line from a patient
with relapsed monoblastic leukemia [23]. The cell can be induced to differentiate by the
phorbolester 12-0-tetradecanoylphorbol 13-acetate treatment [24]. Surface marker analysis with
45 monoclonal antibodies and several polyclonal antisera and isoenzyme analysis of carboxylic
esterase, acid phosphatase, and hexosaminidase and lactate dehydrogenase demonstrated CTV-1
to be of monocytoid origin arrested at a very early stage of differentiation [24].
The results clearly demonstrate a difference in the mechanism driving CTV-1 and THP-1
proliferation. While the difference could be related to the differences in their classification in
M5a (CTV-1) and M5b (THP-1), in their degree of maturity (THP-1 being more mature), or
other developmental differences, it is more likely that the difference reflect the unique lineage of
CTV-1. The lineage of CTV-1 is controversial and our results provide additional information on
this controversy. After its initial establishment, various characterizations demonstrated CTV-1 to
be an M5 type of AML [23-24]. A 2005 study by Andersson A. et al. examined the gene
expression profiles of a large number of leukemia cell lines and patients, and identified the
genomic and expression profiles of various types of leukemia [50]. It found that CTV-1 did not
segregate with its leukemia type, AML. Instead, it segregated with the T-cell acute lymphoid
leukemia, in that they share a common characteristic of Lck up-regulation. This observation has
led to the question of the lineage of CTV-1 cells. Our results further expand on this observation
and demonstrate that Lck is not only over-expressed in CTV-1 cells, it is actually the driver of
CTV-1 proliferation. A study by Palomero T et al. [51] demonstrated that CTV-1 could also be
an example of lineage switching, a rare but well documented phenomenon. Three (ML1, ML2,
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and CTV-1) of 23 AML cell lines they studied were derived from M5 AML relapse in patients
initially diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). All three cell lines
contain activating NOTCH1 mutations that are frequently found in T-ALL cells. The molecular
mechanism of lineage switching is not well understood, and if this hypothesis is true, CTV-1
would be a suitable cell model for investigating the molecular mechanisms of this phenomenon.
If the CTV-1 cell line is indeed is the product of a lineage switching initiated from a Tcell acute lymphoid leukemia, then the characteristics of the CTV-1 cells may not be
representative of a typical M5 AML cell line. Further studies would be necessary to determine if
this is the case.

4.3. Lck and Src family kinases in cancer
The Src family kinases have long been recognized to be potent oncoproteins and their
activation is often associated with various human tumors. It is well established that Src family
kinases constitutively activated either by mutation or overexpression cause cell transformation
[52]. However, naturally occurring SFK activation by mutations as a cause of cancer is rare [5356]. This conclusion is also supported by recent genomic data of 1020 cancer cell lines. Only 26
Src coding mutations were discovered, and none have been shown to be responsible for driving
proliferation. In contrast, the same set of cell lines contained 707 P53 mutations, 142 KRAS
mutations, and 125 PTEN mutations. Despite the very low mutation rate, 112 samples displayed
Src overexpression while only 15 displayed Src under-expression.
An examination of the Lck mutation and expression data provides an interesting
perspective on the uniqueness of CTV-1 as an Lck driven cancer cell line. Out of 1020 cell lines,
tested, only 33 contain Lck mutations and no amino acid mutation occurs more than once. Out of
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970 cell lines for which the Lck expression level has been determined, only 36 yield expression
data, with 16 cell lines overexpressing Lck (Z-score > 2) and 20 under-expressing Lck (Z-score
<-2). Of the 16 over-expressers, 14 are lymphoid cells and 2 are myeloid cells. CTV-1 is the
highest over-expresser with a Z-score of 3.88. The reason majority of the cells did not yield data
is likely due to the fact that those cells do not express Lck. Based on this reasoning, only
lymphoid and myeloid blood cells appears to express Lck. The tissue distribution of Lck
expression data is shown in Fig. 5. Based on this information, it appears that CTV-1
overexpressing and dependent on mutation-activated Lck is likely an uncommon mechanism.
Nevertheless, this cell line can serve as a model system for investigating the biology of Src
family kinases.
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Figure Legends

Figure legends:
Fig. 1. Dose response curves of CTV-1 and THP-1 cell proliferation to protein tyrosine
kinase inhibitors. Cell proliferation assay was performed as described in Materials and Methods.
The cell viabilities after 72-h incubation in the presence of 0.0006 -20 M of PTK inhibitors
were determined by staining cells with Biolog Redox dye as described. For easy comparison, the
CTV-1 and THP-1 responses to the same set of drugs are presented side by side. For purpose of
clarity, the ten drugs tested were presented in two panels 1A and 1B. The inhibitors and their
binding affinity toward cancer census PTKs are detailed in Table 1.

Fig. 2. Inhibition of cell proliferation by Lck-specific inhibitors and Lck expression in AML
cells. A. Inhibition of CTV-1 cell proliferation by Lck-specific inhibitors, A-770041 and WH-4023. The cells were incubated with a series of drug concentrations for 72 h, before the cell
viability was determined using Biolog Redox Mix A. B. Inhibition of GDM-1 cell proliferation
by dasatinib and A-770041. C. Lck expression in CTV-1, THP-1 and GDM-1 detected by
Western blot. The antibody used is specific for Lck. Each lane contained cell lysate from
approximately 6.25x106 cells. -actin expression level as a control was detected by a -actin
specific antibody.

Fig. 3. Phosphorylation of an Lck peptide substrate by CTV-1 and THP-1 cell lysates. The
ability of CTV-1 (A) or THP-1 (B) cell lysates to phosphorylate an Lck-specific peptide
substrate and the sensitivity of this activity to inhibition by Lck inhibitors were determined. The
Lck peptide substrate was expressed as a fusion protein at the C-terminal end of glutathione Stransferase. The cell lysate were incubated with the purified Lck peptide substrate for 30 min
1

under phosphorylating conditions in the presence or absence of the Lck inhibitors. The total
proteins from the phosphorylation reactions were fractionated by SDS-PAGE, and proteins
phosphorylated on Tyr were detected by Western Blotting using an antibody for phosphotyrosine.
The Lck inhibitors dasatinib and A-770041 at 1 M were included as indicated.

Fig. 4. Kinase activity of wt Lck and the effects of CTV-1 mutations on Lck activity. A.
Ribbon structure of Src, illustrating the position of the four Lck mutations found in CTV-1 cells.
The Src structure was generated from the Src structure coordinates (PDB ID: 2Src) [43] using
the Discovery Studio Visualizer. The overall structures of Lck and Src are similar. B. The effects
of CTV-1 mutations on Lck kinase activity. The full length human Lck coding sequence was
cloned into pGEX-4T-1, and was expressed as a GST-Lck fusion protein. Mutations found in
CTV-1 Lck were introduced into the pGEX-Lck. The wt and mutant Lck variants were expressed
in E. coli strain DH5 and purified as GST fusion proteins. The kinase activity of the purified
proteins was determined by Western Blotting as described in Materials and Methods. C. Relative
kinase activities of wt and mutant Lck. The relative activities were determined by subtracting
control (no peptide lanes) from the peptide substrate band density. The band density was
measured by ImageJ software.

Fig. 5. Lck mRNA expression levels in cancer cells from different tissues. The Z-scores were
plotted as a function the origin of the cell lines. The numbers in parentheses after the names of
the tissue indicate the number of cell lines the data is derived from. Standard deviations of the Zscores in each group were presented. The data was obtained from Catalogue of Somatic
Mutations in Cancer (https://cancer.sanger.ac.uk/cell_lines/sample/overview?id=753548). In the
2

study, the Lck expression was examined in 1020 cell lines. Sixteen cell lines displayed
overexpression, while 20 cell lines displayed under-expression.

3

Table 1

Table 1. Primers used for generating the Lck mutants
P232insCCCAGAAGC Primer (+)
P232insCCCAGAAGC Primer (-)
A353V Primer (+)
A353V Primer (-)
P447L Primer (+)
P447L Primer (-)
A500T Primer (+)
A500T Primer (-)

cctTGCcagaCCCAGAAGCcGcaAaaAcCCCAGAAaCCATGGTGG
CCACCATGGtTTCTGGGgTttTtgCgGCTTCTGGGtctgGCAagg
ATTGCAGAGGGCATGGtGTTCATCGAAGAACAG
CTGTTCTTCGATGAACaCCATGCCCTCTGCAAT
CCAGGAATGACCAACCtTGAAGTCATTCAGAACC
GGTTCTGAATGACTTCAaGGTTGGTCATTCCTGG
GATGACTTCTTCACAaCCACAGAGGGCCAGTACC
GGTACTGGCCCTCTGTGGtTGTGAAGAAGTCATC

Table 2

Table 2. Protein tyrosine kinase inhibitors used in this study.
Inhibitor
Target kinases (Kd in nM)*
BGJ398
FGFR1 (0.9), FGFR2 (1.4), FGFR3 (1), FGFR4 (60)
BMS-754807 IGF1-R (1.8), insulin receptor (1.7), Met (5.6)
Bosutinib

Abl1 (0.12), Abl2 (1.5), EGFR3 (0.77), EphA3 (5.8), Lck (0.59), Src (1), BTK
(4.8)

Crizotinib

Alk (3.3), Met (2.1), Lck (30)

Dasatinib

Abl1 (0.03) Abl2 (0.17), PTK6 (7.8), EGFR3 (18), EphA3 (0.09), CSF1R (0.58),
Kit (0.81), PDGFRA (0.47), PDGFRB (0.63), Lck (0.2), Src (0.21), Btk (1.4)

Imatinib

Abl1 (1.1), Abl2 (10), CSF1R (11), Kit (13), PDGFRB (14)

Linifanib

CSF1R (3.4), FLT3 (0.6), Kit (02), PDGFRA (4.2), PDGFRB (1.9), FLT4 (16),
VEGFR2 (8.1)

Neratinib

EGFR1 (1.1), EGFR2 (6), EGFR3 (7.7), EGFR4 (2.4)

Sunitinib

CSF1R (2.5), FLT3 (0.4), Kit (0.4), PDGFRA (0.8), PDGFRB (0.1), Ret (13),
ITK (13), VEGFR2 (1.5)

TAE684
Alk (1.1), Fes (4.8), Jak2 (16), Jak3 (17), FLT3 (15)
*The target cancer census PTKs with Kd values below 20 nM are listed for each inhibitor. The
number in the parenthesis following each PTK is the Kd in nM.
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